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Abstract
Background: Vascular pathology and dysfunction are direct life-threatening outcomes resulting from atherosclerosis or
vascular injury, which are primarily attributed to contractile smooth muscle cells (SMCs) dedifferentiation and proliferation
by re-entering cell cycle. Increasing evidence suggests potent protective effects of G-protein coupled estrogen receptor 1
(GPER) activation against cardiovascular diseases. However, the mechanism underlying GPER function remains poorly
understood, especially if it plays a potential role in modulating coronary artery smooth muscle cells (CASMCs).
Methodology/Principal Findings: The objective of our study was to understand the functional role of GPER in CASMC
proliferation and differentiation in coronary arteries using from humans and swine models. We found that the GPER agonist,
G-1, inhibited both human and porcine CASMC proliferation in a concentration- (1028 to 1025 M) and time-dependent
manner. Flow cytometry revealed that treatment with G-1 significantly decreased the proportion of S-phase and G2/M cells
in the growing cell population, suggesting that G-1 inhibits cell proliferation by slowing progression of the cell cycle.
Further, G-1-induced cell cycle retardation was associated with decreased expression of cyclin B, up-regulation of cyclin D1,
and concomitant induction of p21, and partially mediated by suppressed ERK1/2 and Akt pathways. In addition, G-1 induces
SMC differentiation evidenced by increased a-smooth muscle actin (a-actin) and smooth muscle protein 22a (SM22a)
protein expressions and inhibits CASMC migration induced by growth medium.
Conclusion: GPER activation inhibits CASMC proliferation by suppressing cell cycle progression via inhibition of ERK1/2 and
Akt phosphorylation. GPER may constitute a novel mechanism to suppress intimal migration and/or synthetic phenotype of
VSMC.
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Estrogen (17b-estradiol or E2) lowers the risk of cardiovascular
disease in women [3], and inhibits VSMC proliferation following
injury [4–10]. Interestingly, the anti-proliferative action of E2
persists in ERa-deficient, ERb-deficient, or ERa/ERb-doubleknockout mice [11–13]. Thus, the anti-proliferative effect of E2
may involve a novel ER protein. The recently discovered G
protein-coupled estrogen receptor 1 (GPER) is a seven transmembrane-domain G protein receptor structurally unrelated to ERa or
ERb, binds E2 with high affinity, and mediates estrogenic
signaling [14,15]. The selective GPER agonist, G-1, lowers blood
pressure in either normotensive [16] or mRen2. Lewis hypertensive rats [17], whereas GPER gene knockout female mice exhibit
increased blood pressure–presumably due to increased total vascular
resistance associated with arterial wall remodeling [18]. In addition,
G-1 improves functional recovery from myocardial ischemiareperfusion by reducing post-ischemic contractile dysfunction and

Introduction
Vascular smooth muscle cells (VSMCs) constitute the major
structural component of the vasculature, and are crucial to
maintaining vessel tone, blood pressure, and blood flow. Adult
VSMCs retain remarkable plasticity, and can undergo profound
and reversible phenotypic changes in response to local environmental stimuli. Normally, VSMCs exhibit a ‘‘contractile’’ or
differentiated phenotype characterized by the expression of
specific contractile markers (e.g., myosin heavy chain and a-actin)
[1]; however, injured VSMCs dedifferentiate and re-enter the cell
cycle with an increased rate of proliferation and migration.
Further, expression of myosin heavy chain and a-actin is
decreased in the proliferative stage. This dedifferentiated phenotype plays a major pathophysiologic role in the development of
atherosclerosis, restenosis after angioplasty, and hypertension [2].
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Digital Imaging workstation (Carl Zeiss) equipped with a HQ
CoolSnap camera (Photometrics) and a 56 objective. Five images
per treatment were collected before and after 48 h following
removal of the inserts. Within a specific image five different
distances were measured from the edge marked by a dotted black
line. Data collected represent the mean distance traveled from the
edge.

infarct size [19]. Thus, GPER is a potential mediator of estrogen
action on coronary arteries, but whether GPER plays a role in
coronary artery smooth muscle cell (CASMC) proliferation is
unknown.
In the present study, we demonstrate that G-1 inhibits seruminduced VSM proliferation in both human and porcine coronary
arteries, and have characterized downstream signaling events. We
have also investigated the effect of G-1 on the re-differentiation
and migration of CASMC. Our data provide new insight into the
mechanisms of estrogen receptor signaling in VSMC, and reveal
GPER to be a target for the development of therapeutic strategies
in vascular diseases.

Western blot analysis
After human CASMCs (16105) were cultured in a 6 cm
diameter dish for 48 h, they were starved in serum-free medium
for another 48 h. Cells were then treated with G-1 (1 mM, from
Calbiochem) and PDGF-BB (10 ng/ml, from Sigma-Aldrich
Corporation). For cell cycle protein extracts, cells were starved
in serum-free medium for 72 h before G-1 treatment. Harvested
cells were disrupted, and the protein concentration was determined using BCA assay according to the manufacturer’s
instructions. Proteins were detected with the following antibodies:
anti-cyclinB1 (sc-7393 Santa Cruz, 1:200), anti-cyclin D1 (sc20044 Santa Cruz, 1:200), anti-p21 (sc-6246 Santa Cruz, 1:100),
anti-pERK1/2 (No. 9101s Cell Signaling, 1:1000), anti-pAKT
(No. 4060s Cell Signaling, 1:1000), anti-a-actin (ab5694 Abcam,
1:4000), anti-SM22a (ab14106 Abcam, 1:5000), anti-b-actin
(ab8227 Abcam, 1:1000), or anti-GAPDH (sc-25778 Santa Cruz,
1:1000). After chemiluminescence detection (EMD Millipore,
Billerica, MA, USA), Image J software was used for data analysis.
The experiments were replicated three times.

Materials and Methods
Reagents
Recombinant human PDGF-BB was purchased from Sigma
Company. G-1 was purchased from Cayman Chemical Company
and dissolved in DMSO, and the concentration of DMSO was less
than 0.05% in the control and drug-containing medium.

Isolation of porcine CASMCs and culture of porcine and
human CASMCs
Porcine hearts were obtained from and permitted by local
abattoirs, K&C meat processing. Coronary arteries were dissected,
and CASMCs were enzymatically dispersed [20]. Primary
cultured porcine CASMCs (PCASMC) and human CASMCs
(HCASMC, Cascade Biologics, C-017-5C) were maintained in
Medium 231 with Smooth Muscle growth Supplement (SMGS)
(GIBCO USA), 100 mg/ml penicillin and 100 mg/ml streptomycin. Cell cultures were kept at 37uC and under 5% CO2 in a
humidified incubator. CASMCs were cultured to 80% confluence,
and we employed passage 2–3 for porcine CASMCs or passage 6–
8 for human CASMCs.

Immunocytochemistry
Human and porcine CASMCs seeded on 12 mm glass
coverslips placed in 6 well plates were serum-deprived for 48 h,
and then treated for 1–2 days with vehicle, SMDS, or G-1in
phenol red free MEMa medium. Cells were then fixed in 10%
buffered formalin for 10 min, washed twice with PBS, and
permeabilized in 0.2% Triton X-100 and PBS for 10 min.
CASMCs were washed twice with PBS, and incubated with 4%
BSA-PBS for 1 h, then with anti-a-actin antibody overnight at
4uC and incubated with FITC-conjugated anti-rabbit IgG
antibody (PA1-29388 Thermo Scientific Pierce) for 1 h at room
temperature in darkness. After three washes with PBS, the
coverslips were mounted for imaging.

Cell proliferation assay
CASMCs were seeded onto 6-well plates (16105 cells per well)
for 24 h for attaching and then serum-deprived in phenol red free
MEMa medium (GIBCO USA) for 72 h before treatment with
G-1 or PDGF-BB (10 ng/ml) with 10% Charcoal Stripped FBS
(FCS) (GIBCO USA). Cell proliferation was determined by daily
counting the number of cells in triplicate.

Transfection of siRNA

Cell cycle progression analysis

Human CASMCs were transfected in 6- or 12-well dishes at
30–60% confluence with 75 nM siRNA using Lipofectamine 2000
(Invitrogen) according to the manufacturer’s instructions. The cells
were studied 48 h after transfection. Transfected cells were then
treated with G-1(10 nM or 1 mM) for 48 h. For determination the
effect of silencing GPER on decreased PCNA expression and cell
morphology change caused by G-1 treatment, immunocytochemistry was carried out as described above. For determination of
silencing efficiency, Western blotting was performed and membrane was probed with GPER antibody.

Cell cycle progression assay was performed by RNase staining
followed by FACS (fluorescence-activated cell sorter) analysis.
Distribution of CASMCs cells in the cell cycle was determined by
flow cytometry of propidium iodide-stained nuclei as described by
Odenlund et al [21]. Briefly, flow-cytometric DNA analysis was
performed in a FACS Calibur flow cytometer equipped with data
acquisition capability.

Cellular migration analysis
Analysis of cellular motility/migration was carried out using
Culture-Inserts ready to use in a m-Dish 35 mm (ibiTreat, item #:
81176, IBIDI), which allows performing high resolution microscopy in a 35 mm Petri–dish with 12 mm walls. PCASMCs were
seeded in Medium 231 with SMGS (GIBCO USA), 100 mg/ml
penicillin and 100 mg/ml streptomycin. When cells reached 100%
confluence, the inserts were taken out and a 500 mM gap was left
in each dish. Cells were then grown in fresh control media, or
media+drug treatment (e.g., G-1 or G-1+G-15), and cells were
allowed to migrate for 48 h. Images were collected with a Stallion
PLOS ONE | www.plosone.org

Statistics analysis
Data are presented as means 6 standard deviation (SD) and
analyzed with Prism program (GraphPad Software Inc., San
Diego, CA). One-way or 2-way analysis of variance (ANOVA)
followed by Tukey’s multiple comparison test paired with repeated
measures were carried out for statistical analysis as appropriate. P
values less than 0.05 were regarded as statistically significant.
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Figure 1. Reduced proliferation and delayed cell cycle progression of G-1 treated CASMCs cells. A: Cell proliferation curves of G-1 and/or
PDGF-BB treated HCASMC cells. CASMCs were synchronized by 3 days of culturing in serum free and phenol red-free DMEM medium. Then 10% fetal
calf serum (FCS) was added into medium and cells were counted manually with trypan-blue method (trypan-blue method of exclusion). B, E and G:
HCASMC (B) and PCASMC (E, G) cell cycle distribution was determined by propidium iodide staining of DNA content and flow cytometry. After
synchronized, 10% FCS was added and cells were treated with vehicle as control (C); G-1 (G, 1028–1025 M); 10 ng/ml PDGF-BB (P) or 1 mM G-1 plus
10 ng/ml PDGF-BB (G+P) at 24 or 48 hours. Twenty-thousand cells per sample and three replicates per group were collected. Representative
histograms are shown in C (G-1 concentration response); D, G+P, 1 mM G-1 plus 10 ng/ml PDGF-BB, for 48 h treatment of HCASMC; F, 24 hour
treatment and H, 48 hour treatment of PCASMC with 1 mM G-1 plus 10 ng/ml PDGF-BB. Representative histograms are shown as the mean 6SD
(n = 3), a significant difference is indicated by either *p,0.05; ** p,0.01 or ***p,0.001, one-way or two-way ANOVA.
doi:10.1371/journal.pone.0064771.g001

Furthermore, G-1 significantly suppressed 10% FCS plus 10 ng/
ml PDGF-BB-induced cell proliferation, as evidenced by a marked
decrease of cell population in S phase (p,0.01, n = 4). These data
indicate that G-1 significantly inhibits the proliferation of porcine
CASMCs by slowing down the progression of the cell growth cycle
from G0/G1 to S and G2/M-phase. Together with the data from
human CASMCs, these data suggest that G-1-activated GPER
can inhibit proliferation by controlling cell cycle progression in
CASMCs in a concentration- and time-dependent manner.

Results
GPER activation reduces CASMC proliferation
We examined the action of GPER in controlling both primary
human and porcine CASMC proliferation. Human CASMCs
(passage 6–8) treated with G-1 displayed reduced cell growth
(Figure 1A), for example, treating cells with 1 mM G-1 for 24 h
reduced cell growth by 26%. In contrast, the pro-proliferative
agent platelet-derived growth factor (PDGF-BB, 10 ng/ml, 24 h
treatment) increased cell number by 22%. These results indicate
that activation of GPER by G-1 represses cell proliferation of
human CASMCs.
The suppressive effect of G-1 on CASMCs was further
investigated by analyzing cell cycle progression (Figure 1;
table 1–3). Cells were cultured in 10% FCS after synchronization.
G-1 (1025 M) significantly decreased the proportion of human
CASMCs in phases S and G2/M by 58.76% and 44.75%
respectively after 48 h treatment (G-1 vs control, P,0.05, n = 3;
Fig. 1B, 1C). The addition of 10 ng/ml PDGF-BB in 10% FCS
medium clearly stimulated cell growth with a marked increase in
the cell proportion of S phase and G2/M cells at 48 h (Figure 1B,
1D; table 1). Although data indicated a clear trend for 1 mM G-1
48 h treatment lowering the proportion of stimulated cells in
G2/M phase, this effect did not reach statistical significance
compared to controls (Figure 1B, 1D). The relative higher passage
of the human CASMCs might have contributed to the lesser
effectiveness of G-1 on the addition of PDGF-BB in 10% FCS
compared to 10% FCS alone stimulated cell growth.
Swine models of coronary dysfunction are similar to those of
humans in response to injury or pathophysiological conditions
[22]. Therefore, we also employed primary porcine CASMCs and
tested for GPER activation at a low passage (p2) (Figure 1E–1H;
table 2–3). Compared to human CASMCs, the anti-proliferative
effect of G-1 on porcine CASMC was more robust. Treatment
with G-1 (1027, 1026, or 1025 M) alone significantly decreased
the proportion of S phase cells at 24 h and G2/M-phase cells at
48 h, while increased accumulation of cells at G0/G1 phase.

GPER activation represses cell cycle progression by
inducing expression of p21 in human and porcine
CASMCs
There is increasing evidence for a critical role of the cyclindependent kinase inhibitor (CDK-I) p21 in repressing VSMC
growth [23,24]. Accordingly, we examined whether p21 and other
cell cycle regulatory molecules (i.e., the G1-phase–specific cyclin
D1, and the G2/M-phase–specific cyclin B1) are involved in antiproliferative effects of GPER. Human CASMCs growth was
synchronized by 3-day serum deprivation, and then cells were
treated with 1 mM G-1 in 10% FCS. Cells were collected at 6, 24,
48, or 72 hours for immunoblot analysis (Figure 2A and 2B).
Immunoblot studies revealed that p21 proteins were up-regulated
in G-1-treated cells at all-time points compared to vehicle-treated
cells (Figure 2B). Unexpectedly, G-1 treatment increased cyclin D1
level (Figure 2B), but almost completely prevented cyclin B1
accumulation (Figure 2B). These data indicate that GPER
activation by G-1 treatment accumulates cell population in G1
phase, but hinders the cell cycle from entering G2/M phase.
We then tested these effects of G-1 on porcine CASMCs. The
protein levels of cell cycle regulatory molecules were examined at
24 and 48 hours by immunoblot analysis (Figure 2C and 2D). As
expected, PDGF-BB clearly up-regulated expression of both
cyclins D1 and B1, while p21 expression was down-regulated
compared to controls (Figure 2D), further confirming the cell cycle
accelerating effect of PDGF-BB in CASMCs. G-1, on the other
hand, not only increased p21 expression and nearly prevented

Table 1. The effect of G-1 treatment on human CASMCs for 48 hours.

G0/G1
Mean+SD

S

G2/M

Change after
treatment (%)

Mean+SD

Change after
treatment (%)

Change after
treatment (%)

Control

82.27+5:58

G 1028

84.58+1:68

2.81

9.00+1:58

28.35

6.42+1:00

218.84

G 1026

85.03+2:81

3.26

6.64+1:76

232.38

8.33+1:10

5.31

25

9.82+3:96

Mean+SD
7.91+1:64

91.58+1:80

10.95

4.05+0:58

258.76

4.37+1:39

244.75

PDGF

79.77+2:46

22.96

7.78+2:47

220.77

12.45+2:2

57.40

G1026+P

72.27+9:41

212.54

9.78+4:10

20.41

11.90+1:87

50.44

G 10

doi:10.1371/journal.pone.0064771.t001
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Table 2. The effect of G-1 on porcine CASMCs after 24 hour treatment.

24 h

G0/G1
Mean+SD

C

S
Change after
treatment (%)

75.15+2:77

G2/M
Change after
treatment (%)

Mean+SD
20.68+0:49

Mean+SD

Change after
treatment (%)

4.51+0:67

27

69.68+4:17

27.28

20.56+0:92

20.58

5.01+1:53

11.09

G 1026

81.93+0:24

9.02

16.12+1:32

222.05

5.09+0:61

12.86

G 1025

88.43+3:70

17.67

8.88+0:85

257.06

3.84+0:08

214.86

P

54.80+3:48

227.08

33.69+1:48

62.91

12.96+0:33

187.36

G1026+P

56.76+2:60

224.47

24.40+3:20

17.99

13.63+0:27

202.22

G 10

doi:10.1371/journal.pone.0064771.t002

phosphorylation induced by 10% FCS or 10% FSC plus 10 ng/ml
PDGF-BB in porcine CASMCs. G-1 (1027–1025 M) inhibited
FCS-induced phosphorylation of ERK1/2 and Akt in a concentration-dependent fashion. Moreover, G-1 inhibited the enhanced
phosphorylation of Akt and ERK induced by the addition of
10 ng/ml PDGF-BB in 10% FSC medium (Figure 3C). These
results demonstrated that the inhibitory effects of GPER activation
by G-1 in CASMCs are mediated by suppressing ERK1/2 and
Akt activation.

cyclin B1 accumulation at both 24 and 48 hours (in the presence
of 10% FCS), but also inhibited the effects of PDGF-BB on p21
and cyclin B1 in a similar concentration-dependent manner
(Figure 2D). However, the effect of G-1 on PDGF-BB-induced
cyclin D expression was not significant (Figure 2D). Taken
together, our results demonstrate that G-1 blocks cell cycle
progression in late G1 phase before cyclin D1 degradation occurs
and before cyclin B1 accumulates.

GPER activation decreases phosphorylation of AKT and
ERK1/2

G-1 stimulation changes CASMC morphology by
increasing the protein level of a-Actin and SM22

To understand the pathways that mediate GPER activation
regulated cell proliferation, we next examined the effects of G-1 on
extracellular signal-regulated protein kinases (ERKs)-1 and 2
(ERK1/2) and Akt – two signaling systems that powerfully impact
cell proliferation in breast and prostate cancer cells [25–27]. After
serum deprivation, human CASMCs (passage 7–8) were treated
with 10 ng/ml PDGF-BB for the indicated times (total period of
60 minutes) in the presence of 10% FCS. Control groups were
treated with vehicle only. PDGF-BB-treated cells showed a
significant increase of phosphorylated Akt and ERK1/2 over
60 min compared to controls (Figure 3A; P,0.05, n = 3). In
contrast, human CASMCs treated with 1 mM G-1 exhibited
decreased phosphorylation of both ERK1/2 and Akt at each time
point, with the exception of p-Akt at 2-minutes, compared to
vehicle-treated controls (Figure 3B).
Because our cell cycle results revealed a stronger G-1 effect in
porcine CASMCs (passage 2) compared to human CASMCs
(passage 7–8), we next tested the effect of G-1 on ERK1/2 and Akt

Several lines of evidence suggest that p21 up-regulation and cell
cycle arrest are necessary for cell differentiation [28,29]. Therefore, we postulated that G-1 might contribute to SMC differentiation. To test this possibility, we used Smooth Muscle
Differentiation Supplement (SMDS) to induce differentiation of
normal human and porcine CASMCs [30]. After 3-day synchronization, 10% FCS was added to the medium and cells were then
treated with 10 nM or 1 mM G-1. Vehicle-treated SMCs exhibited
a typical SMC morphology: flattened and spindle shaped with
central oval nuclei and long cytoplasmic extensions. Confluent
cells appear aligned in parallel so that the broad nuclear region of
a cell lies adjacent to the thin cytoplasmic area of another forming
a ‘‘hill-and-valley’’ appearance. Cells treated with SMDS
displayed a change in cellular morphology from slender stellate
cells to enlarged rectangular-shaped cells. Furthermore, immunocytochemistry demonstrated increased amounts of smooth muscle
a-actin. A more contractile phenotype and increased a-actin was

Table 3. The effect of G-1 on porcine CASMCs after 48 hour treatment.

48 h

G0/G1
Mean+SD

S
Change after
treatment (%)

G2/M

Mean+SD

Change after
treatment (%)

Mean+SD

C

65.86+0:16

G 1027

75.40+0:32

14.49

17.53+0:82

231.20

7.07+1:14

218.36

G 1026

82.42+2:94

25.14

12.66+0:84

250.31

4.92+2:09

243.19

G 10

25

25.48+1:74

Change after
treatment (%)

8.66+1:91

85.94+1:56

30.49

9.27+0:75

263.62

4.79+1:00

244.69

P

59.10+0:19

210.26

31.08+0:29

21.98

9.82+0:10

13.39

G1026+P

66.48+0:42

0.94

22.93+1:17

210.01

10.59+0:74

22.29

The numbers in Tables 1–3 are from Figure 1 B–H.
doi:10.1371/journal.pone.0064771.t003
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Figure 2. Effects of G-1 treatment on the protein level of cyclinB1, cyclinD1 and p21 in CASMCs. A and C: Western blot results of
cyclinB1, cyclinD1 and p21 protein levels in human CASMCs (A) and porcine CASMCs (C). CASMCs were synchronized by 3 days of cultivation in
serum-free and phenol red free medium followed by vehicle treatment as control (C); G-1(G, 1027–1025 M); 10 ng/ml PDGF-BB (P); and G-1(1027–
1025 M) plus 10 ng/ml PDGF treatment (GP or P+G) for 24 or 48 hours in the presence 10% FCS. Total cell extracts (16106) were subjected to
Western-blot analyses for cyclinB1, cyclinD1 and p21 level. B and D: Quantitative densitometric analyses of band intensities from 3 independent
experiments. Data are normalized by GAPDH or b-Actin, expressed as the mean6SD (n = 3). A significant difference is indicated by either *(p,0.05);
**(p,0.01) or *** (p,0.001) (one-way ANOVA). Representative histograms are shown.
doi:10.1371/journal.pone.0064771.g002

seen in both G-1-treated groups. Cells showed more enlarged
rectangular or even triangular shaped cells in human CASMCs
(Figure 4, left side two panels). These phenotypic characteristics
were even more pronounced in porcine CASMCs (Figure 4, right
side two panels). After prolonged G-1 exposure some cells
exhibited an increased stacking of a-actin fibers giving the
appearance of a ‘‘bird’s nest’’ shape, and the upper panels of G1 (10 nM and 1 mM)-treated human and porcine CASMCs were
selected areas for this ‘‘bird’s nest’’ shape morphology change.
Further, G-1 produced a much greater increase of smooth muscle
a-actin and SM22 a than that of cells treated with SMDS alone
(Figure 5). For example, a-actin expression induced by 10 nM G-1
(2-day treatment, human and porcine CASMCs) was 46.62% and
79.23% greater, respectively, compared to a-actin expression in
SMDS-treated cells P,0.01 (n = 3). Collectively, these data
demonstrate that GPER activation induces a differentiated VSMC
phenotype.

Discussion
GPER is a G protein-coupled receptor functioning independently from ERa and ERb to regulate cellular and physiological
responsiveness to estrogen [14,30]. To our knowledge, this study is
the first to demonstrate effects of a selective GPER agonist, G-1,
on coronary artery SMC differentiation, proliferation and
migration, and to propose key mediators of this response. Previous
studies indicate that GPER activation promotes cancer cell
proliferation and migration primarily by producing connective
tissue growth factor in a human breast cancer cell line SKBr3
[32,33]. In addition, tamoxifen, an ERa antagonist but GPER
agonist, induces abnormal endometrial thickening and cell
proliferation [34,35]. Expression of both GPER and ERa along
with active EGFR signaling, is required for E2-stimulated and G1–stimulated proliferation of ovarian cancer cells [36]. In contrast
to these proliferative effects, activation of GPER by G-1 inhibits
growth of androgen-dependent and -independent prostate cancer
cells in vitro and PC-3 xenografts in vivo [27]. Thus, GPER
functions in a tissue- or cell-specific manner. In blood vessels the
VSM layer is enlarged in arteries from GPER gene knockout
female mice, indicating that GPER helps maintain VSMCs in a
dedifferentiated state [18]. In addition, G-1 reduces serumstimulated human umbilical VSMC proliferation [16]. These
findings are consistent with our results of G-1 inhibition of
CASMCs proliferation or migration. Involvement of GPER in
these inhibitory responses to G-1 was substantiated by our
experiments indicating that the effect of G-1 on proliferation
was attenuated in cells expressing GPER siRNA, whereas G-1induced inhibition of migration was inhibited significantly by G15, a selective GPER antagonist.
E2 inhibits serum-stimulated cell growth of human CASMCs by
57% and arrests PDGF-BB stimulated cell cycle at the G1 phase in
human aortic VSMC [10]. In contrast, we found that G-1 failed to
effectively repress cell cycle progression after 24 hours in human
CASMCs (passage 7–8). However, G-1 (24 hours) effectively
inhibited serum-induced growth of primary CASMC from pig
coronary artery, but failed to inhibit serum plus PDGF-induced
cell growth of these cells. These findings indicate that the antiproliferative effect of G-1 on VSM is distinct from that of E2, and
suggest a stronger anti-proliferative effect compared to G-1.
Nonetheless, Haas et al. [16] found that G-1 reduced proliferation
of human umbilical vein SMCs by 60–80%. Interestingly, these
cells lose expression of ERa and ERb in culture, yet retain full
GPER expression. Therefore, it appears that activation of GPER,
like nuclear ER, exerts an anti-proliferative effect on VSM;
however, it appears that when all three estrogen receptors are coexpressed that the nuclear receptors play the more dominant role
in slowing proliferation. At present, however, potential cross-talk
between GPER and ERa or ERb and signaling events
downstream from GPER activation in VSMC is unknown.
Potential effects of G-1 on downstream signaling events are also
unknown.
Our flow cytometry results indicate that G-1 increases the
number of cells in the G1-phase, and hinders cell cycle transition
into the S phase and G2/M phase. Moreover, G2/M phase-

GPER activation inhibits PCNA expression in CASMCs
Proliferating cell nuclear antigen (PCNA) expression increases
as mitogens (such as PDGF) or serum stimulates VSMC
proliferation [31]. In order to determine the effect and specificity
of G-1 on proliferation we knocked-down expression of GPER via
siRNA transfection studies, and then determined the effect of G-1
on PCNA expression and cell morphology in serum-stimulated
human CASMCs. In control cells transfected with non-target
siRNA, 10 nM or 1 mM G-1 clearly decreased serum-induced
increases in PCNA expression, (Figure 6 A, B) and also changed
cell morphology into a more enlarged rectangular shape. In
contrast, G-1 failed to exert an inhibitory effect on PCNA
expression in cells transfected with GPER siRNA, and the effect
on cell morphology was less compared to controls (Figure 6A).
Western blotting confirmed the efficiency of GPER silencing with
siRNA, as GPER expression deceased by 65–69.3% (Figure 6C).
Collectively, these results strongly suggest that G-1 inhibits
CASMC proliferation via a GPER-mediated mechanism.

GPER activation inhibits CASMC migration
Vascular smooth muscle cell migration accompanies proliferation, and plays important role in the pathogenesis of atherosclerosis or arterial injury. Therefore, we tested the effect of G-1 on
migration of porcine CASMCs. Cells were seeded on 35 mm
dishes with Culture-Inserts, and grown in Medium 231 with
SMGS. When cells reached 100% confluence, the inserts were
removed leaving a 500 mM gap in the growing cell population.
Fresh growth medium was then added to the cells, which were
exposed to different treatment conditions (Figure 7). After a 48 h
incubation, cells from the control group migrated to the center of
the dish, but did not fully cover the gap. 1 mM G-1, however,
completely inhibited cellular migration stimulated by the growth
medium (p,0.05; Figure 7B). Addition of 5 mM G15 to the
growth medium did not affect control cell migration; however, the
inhibitory effect of G-1 on cellular migration was attenuated
significantly by G15 (p,0.05). Collectively these results suggest
that GPER activation inhibits CASMC migration.
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Figure 3. G-1 inhibits the phosphorylation of Akt and ERK1/2 in CASMCs. A and B: HCASMCs were cultured in serum and phenol red free
medium for two days followed by PDGF-BB (10 ng/ml) (A) or G-1 (1 mM) treatment (B) for indicated time in the presence of 10% FCS. C: PCASMCs
were cultured in the same medium for two days followed by G-1(1027–1025M); PDGF-BB (10 ng/ml); and G-1(1027–1025M) plus PDGF-BB (10 ng/ml)
treatments for indicated time in the presence of 10% FCS. Total cell extracts (16106) were subjected to Western-blot analyses for Phospho-Akt and
ERK1/2 level. Under the Western blot panels, a quantitative representation of the expression analysis from 3 independent experiments is shown.
Vehicle-treated CASMCs cells were used as control. Data are normalized by b-Actin and expressed as means 6SD (n = 3). A significant difference is
indicated by either **** p,0.0001, *** p,0.001, ** p,0.01 or * p,0.05(one or two-way ANOVA); C, G and P represent control, G-1 and PDGF-BB
treatment sample respectively, ns indicates no significant difference.
doi:10.1371/journal.pone.0064771.g003

Figure 4. Effect of G-1 treatment on cell morphology in cultured CASMCs. Human and porcine CASMCs were incubated in the presence of
either a SMDS or G-1 (1 mM and 10 nM) for 1 and 2 day followed by immunostaining using anti-a-smooth muscle antibody and FITC-conjugated antirabbit IgG secondary antibody (green).
doi:10.1371/journal.pone.0064771.g004
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Figure 5. Effect of G-1 treatment on the protein level of a-smooth muscle actin and SM22a in CASMCs. A and D: changes of a-smooth
muscle actin and SM22a protein in SMDS and G-1 treated human (A) and porcine (D) CASMC. Expression of a-smooth muscle actin and SM22a
protein were determined by immunoblot analysis. SM22a and a-smooth muscle actin were increased in G-1 treated cells in a concentration and timedependent manner. SM22a and a-smooth muscle actin expression was quantified by densitometric analysis from 3 independent experiments. Data
are normalized by GAPDH (HCASMC) and b-Actin (PCASMC), expressed as the mean 6SD (n = 3). *P,0.05, **P,0.01 vs control (one-way ANOVA).
Representative histograms are shown in B, C and E, F.
doi:10.1371/journal.pone.0064771.g005

specific cyclin B1 was strongly down-regulated by G-1. Cell-cycle
progression from the G1-phase of the cell cycle to S phase entry is
tightly regulated by cyclin-dependent kinases and their cyclinregulatory subunits. Because cyclin B1 is essential for G2/M phase
transition entry into mitosis, our finding of G-1-induced downregulation of cyclin B1 is consistent with an anti-proliferative effect
of G-1 on CASMCs. In addition to cyclin B1, cyclin D1 gene is
frequently overexpressed in VSMC under growth factor stimulation, and its down-regulation has been proposed to be associated
with G1-phase arrest of cell growth [37,38]. Unexpectedly, we
found that expression of G1-S phase specific cyclin D1 was upregulated by G-1 in VSMCs. Obviously, cyclin D1 was not involved
in G-1-induced inhibition of cell cycle progression from G1- into
S-phase. This finding seems to differ from a previous report where
17b-estradiol suppressed PDGF-stimulated progression from G1- to
PLOS ONE | www.plosone.org

S-phase in human aortic artery smooth muscle proliferation,
possibly by inhibiting PDGF-induced phosphorylation of retinoblastoma protein (pRb) or by reducing cyclin D1 expression [10].
Therefore, GPER may function differently from ERa and ERb:
GPER does not mediate inhibition of cyclin D1 expression nor pRb
phosphorylation in VSMC. Although G-1-induced up-regulation of
cyclin D1 is unexpected, it is not surprising as studies have shown
that cell differentiation can be promoted by up-regulation of cyclin
D1 and p21 [28].
The re-differentiation process of synthetic VSMC is coupled to
withdrawal from the proliferation cell cycle, and we examined how
G-1 affects smooth muscle cell differentiation marker protein
expression in both porcine and human CASMCs. Differentiation
induced by SMDS [39,40] changed cellular morphology from
slender stellate cells to enlarged rectangular shaped cells, and
10
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Figure 6. Down-regulation of GPER reverses the decreased expression of PCNA and cell morphology changes caused by G-1. (A)
HCASMC cells transfected with non-targeted siRNA or GPER siRNA were incubated with G-1 (1 mM or 10 nM) for 48 h, followed by immunostaining
using anti-PCNA antibody and FITC-conjugated anti-rabbit IgG secondary antibody (green). Cells were then stained by acti-stainTM555 Fluorescent
phalloidin for F-actin to reveal cell morphology. Slides were mounted with ProLong Gold anti-fade regent with DAPI (Invitrogen Life Technologies,
Gaithersburg, MD, USA) for imaging. (B) The expression of PCNA were presented as mean fluorescence intensities 6 S.E. of at least 50 cells collected
from at least 5 random areas per sample and were analyzed statistically by ANOVA followed by Tukey’s multiple comparison test. *Indicates
significant difference from control at p,0.05. (C) GPER protein levels were measured by immunoblotting in siRNA-transfected cells 48 h following
transfection.
doi:10.1371/journal.pone.0064771.g006

PLOS ONE | www.plosone.org

11

June 2013 | Volume 8 | Issue 6 | e64771

GPER Function in Artery Smooth Muscle Cell

Figure 7. Effect of GPER stimulation on CASMC migration. (A) Representative of three experiments of porcine CASMC migration study.
Cellular migration was assessed by using scratch-wound assay. Cells were cultured in ibidi m-dish culture insert until they reached confluence. Inserts
(500 mm; dashed lines) were then removed, and cells were exposed to control media or media supplemented with either 1 mM G-1 or 1 mM G-1+5 mM
G15. Five images per treatment were collected immediately and then 48 h following insert removal. Within a specific image five different distances
were measured from the edge of the dashed-line. (B) Each bar represents the mean distance traveled from the edge +/2 SEM. Comparison between
the different treatments was done with One-way ANOVA followed by Tukey’s multiple comparison test, and treatment groups identified by different
letter (a,b, or c) indicate significant difference (p,0.05) between each of the three experimental groups.
doi:10.1371/journal.pone.0064771.g007

VSMC a-actin content was clearly increased, as predicted.
However, G-1 exerted an even stronger effect than SMDS on
cell morphology and a-actin expression in both human and
porcine CASMCs. Collectively, these data certainly demonstrate
that GPER activation induces VSMC differentiation phenotype
and repression of cell cycle progression. The mechanism of how
this repression is coupled to re-differentiation is beyond the scope
of the present study, but evidence suggests that increased p21 and
cyclin D1 expression is correlated with differentiation of various
cell types [29,41,42]. We found increased expression of p21 and
cyclin D1 as early as 6 hours after exposure to G-1, and this effect
persisted up to 72 hours – an effect which correlated with
increased expression of VSMC a-actin and SM22 a at the first and
second day of CASMCs exposure to G-1. Taken together, these
findings suggest that G-1-induced CASMC differentiation is
related to greater expression of p21 and cyclin D1.
GPER has been shown to modulate ERK1/2 and Akt activity,
which is dependent upon trans-activation of the epidermal growth
factor (EGF) receptor via release of heparin-bound EGF (HB-EGF)
in breast cancer cells [25]. We found that although phosphorylation
levels of ERK1/2 and Akt in human and porcine CASMCs
fluctuated somewhat over time, the overall effect of G-1 was to
decrease phosphorylation. Pretreating CASMCs with G-1 led to a
significant concentration-dependent decrease in serum-stimulated

ERK1/2 and Akt phosphorylation. Apparently, GPER exerts a
negative effect on ERK and Akt signaling in the presence of
mitogens in CASMCs. This finding is consistent with studies by
Filardo et al. [26] where GPER activation stimulated adenylyl
cyclase activity in breast cancer cells and suppressed EGF-induced
ERK1/2 activity. Whether cAMP signaling is involved in the G-1
effect on ERK1/2 activity in the CASMCs is an ongoing
investigation in our laboratory. The present study provides new
evidence that GPER plays an important role in regulating coronary
artery smooth muscle growth, and promotes re-differentiation and a
contractile phenotype in these cells. Furthermore, we propose
GPER as a novel therapeutic target to prevent coronary artery
dysfunction.
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